Captopril: Difference between revisions
ClaireLewis (talk | contribs) No edit summary |
Elcatracho (talk | contribs) |
||
| Line 39: | Line 39: | ||
==See Also== | ==See Also== | ||
*[[Hypertension]] | |||
*[[ACE-inhibitors]] | *[[ACE-inhibitors]] | ||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] [[Category:Cardiology]] | [[Category:Pharmacology]] [[Category:Cardiology]] | ||
Revision as of 15:54, 8 March 2021
Administration
- Type: ACE inhibitor
- Dosage Forms: tablet
- Dosage Strengths: 12.5, 25, 50, 100mg
- Routes of Administration: PO
- Common Trade Names: Capoten, Captoril
Adult Dosing
- 6.25-150mg PO three times per day
Pediatric Dosing
Safety/efficacy not established in pediatric patients
Special Populations
- Pregnancy Rating: D
- Lactation risk: Infant risk minimal
- Renal dosing: Initial dose should be reduced, titrate in smaller increments
Contraindications
- Allergy to class/drug
- History of ACE-inhibitor induced angioedema
Adverse Reactions
Serious
- Angioedema
- Stevens-Johnson syndrome
- Agranulocytosis, neutropenia
Common
- Hypotension
- Hyperkalemia
- Cough
- Rash
Pharmacology
- Half-life: < 3 hours
- Metabolism: Hepatic
- Excretion: Renal, dialzable
Mechanism of Action
- Inhibits angiotensin I-converting enzyme, blocks conversion of angiotensin I→ angiotensin II